HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced it has been granted a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. This expanded capability is designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without altering its existing form factor.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. According to the company, the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications, and device hardware.
This development is significant because heart failure and structural heart disease affect millions worldwide, and early detection is critical for effective management. HeartBeam’s technology aims to provide patients and physicians with a tool that can be used outside of medical facilities, potentially reducing hospitalizations and improving outcomes. The ability to monitor fluid buildup in the chest, a key indicator of worsening heart failure, through a non-invasive, portable device could transform how these conditions are managed.
The company’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
For more details, the full press release is available at https://ibn.fm/jgVf0. Additional information about HeartBeam and its cleared indications for use can be found at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
